title: Haptoglobin-related protein as a serum marker in malignant lymphoma.
abstract: A novel serum 21 kDa haptoglobin-related protein (Hpr) was investigated in patients with malignant lymphoma, to evaluate its correlation with clinical and histologic features at presentation and its possible role as a tumor marker for patient outcome. One hundred fifty eight serum samples were taken from 88 patients with non-Hodgkin's lymphoma (n=58) and Hodgkin's disease (n=30) at presentation and in the course of follow-up. Sera from 61 healthy volunteers served as normal controls. Serum Hpr levels in the lymphoma patients (median 430x10 u/ml, range 0-4000x10 ) were significantly higher than in the control group (median 68x10 u/ml, range 0-180x10 )(p=0.0001). Higher median Hpr values were detected in patients with advanced disease (p=0.013), "B" symptoms (p=0.029) and in males (p=0.053). There was also a significant correlation between Hpr and erythrocyte sedimentation rate (p=0.028). Serial determinations showed a significant decrease of the initial Hpr values obtained after treatment in 41 patients, 38 of whom achieved complete remission. In the follow-up period additional Hpr measurements were taken from 17 patients. Three of them eventually relapsed, and showed increased Hpr levels at the time of relapse. Hpr levels remained low in 11 of 14 patients who maintained complete remission, and increased in three. In conclusion, serum Hpr is a new serum tumor marker of potential use in the clinical setting of lymphoma.
authors.affiliation: Department of Oncology, Rambam Medical Center, Haifa, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Epelbaum
authors.forename: C
authors.initials: C
authors.lastname: Shalitin
authors.forename: R
authors.initials: R
authors.lastname: Segal
authors.forename: C
authors.initials: C
authors.lastname: Valansi
authors.forename: I
authors.initials: I
authors.lastname: Arselan
authors.forename: D
authors.initials: D
authors.lastname: Faraggi
authors.forename: M
authors.initials: M
authors.lastname: Leviov
authors.forename: M
authors.initials: M
authors.lastname: Ben-Shahar
authors.forename: N
authors.initials: N
authors.lastname: Haim
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics; D001798:Blood Proteins / Q000032:analysis* / Q000235:genetics; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics; D003131:Combined Modality Therapy; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006242:Haptoglobins; D006689:Hodgkin Disease / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy; D006801:Humans; D008223:Lymphoma / Q000097:blood* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood* / Q000235:genetics; D011379:Prognosis; D011878:Radiotherapy; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D001798:Blood Proteins; C058632:HPR protein, human; D006242:Haptoglobins; D009363:Neoplasm Proteins